{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:15:33Z","timestamp":1789409733681,"version":"build-2803163510"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,6,18]],"date-time":"2017-06-18T00:00:00Z","timestamp":1497744000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00277-017-3028-4","type":"journal-article","created":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T22:16:25Z","timestamp":1497737785000},"page":"1253-1270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pathogen reduction\/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?"],"prefix":"10.1007","volume":"96","author":[{"given":"Giovanni","family":"Di Minno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Canaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"G\u00fcrtler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Ironside","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Eichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Tiede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,18]]},"reference":[{"issue":"3","key":"3028_CR1","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1182\/blood-2006-10-050435","volume":"110","author":"SC Darby","year":"2007","unstructured":"Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, Lee CA, Ludlam CA, Williams M (2007) Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 110(3):815\u2013825. doi: 10.1182\/blood-2006-10-050435","journal-title":"Blood"},{"key":"3028_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1750-1172-7-24","volume":"7","author":"M Franchini","year":"2012","unstructured":"Franchini M, Mannucci PM (2012) Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 7:24. doi: 10.1186\/1750-1172-7-24","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"3028_CR3","doi-asserted-by":"publisher","first-page":"9S","DOI":"10.1111\/j.1537-2995.2012.03622.x","volume":"52","author":"RJ Benjamin","year":"2012","unstructured":"Benjamin RJ, McLaughlin LS (2012) Plasma components: properties, differences, and uses. Transfusion 52(Suppl 1):9S\u201319S. doi: 10.1111\/j.1537-2995.2012.03622.x","journal-title":"Transfusion"},{"issue":"1","key":"3028_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.transci.2014.12.016","volume":"52","author":"V Salunkhe","year":"2015","unstructured":"Salunkhe V, van der Meer PF, de Korte D, Seghatchian J, Gutierrez L (2015) Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apher Sci 52(1):19\u201334. doi: 10.1016\/j.transci.2014.12.016","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"3028_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.blre.2015.07.004","volume":"30","author":"G Di Minno","year":"2016","unstructured":"Di Minno G, Perno CF, Tiede A, Navarro D, Canaro M, Guertler L, Ironside JW (2016) Current concepts in the prevention of pathogen transmission via blood\/plasma-derived products for bleeding disorders. Blood Rev 30(1):35\u201348. doi: 10.1016\/j.blre.2015.07.004","journal-title":"Blood Rev"},{"key":"3028_CR6","unstructured":"WHO (2011) Global database on blood safety summary report. http:\/\/www.who.int\/bloodsafety\/global_database\/GDBS_Summary_Report_"},{"key":"3028_CR7","unstructured":"World_Bank (2014) New country classifications by income level. http:\/\/data.worldbank.org\/news\/new-country-classifications"},{"key":"3028_CR8","unstructured":"L\u2019Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM); Rapport d\u2019activit\u00e9 h\u00e9movigilance (2015) Available from: http:\/\/ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/27ce3d0739821882c0cd87041b8050a7.pdf"},{"key":"3028_CR9","unstructured":"Funk M,Lohmann A, Spranger R, Volz-Zang C (2015) Haemovigilance Report of the Paul-Ehrlich-Institut 2013\/2014: Assessment of the reports of serious adverse transfusion reactions pursuant to Section 63i AMG (German Medicines Act). http:\/\/www.pei.de\/SharedDocs\/Downloads\/vigilanz\/haemovigilanz\/publikationen\/haemovigilance-report-2013-2014.pdf"},{"key":"3028_CR10","unstructured":"Piccinini V, Facco G, Catalano L, Gentili S, Marano G, Pupella S, Grazzini G, Liumbruno GM Istituto Superiore Di Sanita (ISTISAN). Haemovigilance in Italy. Report 2014 (Accessed at: http:\/\/www.iss.it\/binary\/publ\/cont\/16_41_web.pdf . http:\/\/www.iss.it\/binary\/publ\/cont\/16_41_web.pdf"},{"key":"3028_CR11","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad de Espa\u00f1a.. Unidad de Hemovigilancia, \u00e1rea Hemoterapia. Subdirecci\u00f3n General de Promoci\u00f3n de la Salud y Epidemiolog\u00eda. Hemovigilancia A\u00f1o 2015. Available from: http:\/\/www.msssi.gob.es\/profesionales\/saludPublica\/medicinaTransfusional\/hemovigilancia\/docs\/Informe2015.pdf"},{"key":"3028_CR12","unstructured":"PHB Bolton-Maggs (Ed) D Poles et al. on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2015 Annual SHOT Report (2016). https:\/\/www.shotuk.org\/wp-content\/uploads\/SHOT-2015-Annual-Report-Web-Edition-Final-bookmarked-1.pdf"},{"issue":"4","key":"3028_CR13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/trf.12918","volume":"55","author":"AR Harvey","year":"2015","unstructured":"Harvey AR, Basavaraju SV, Chung KW, Kuehnert MJ (2015) Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012. Transfusion 55(4):709\u2013718. doi: 10.1111\/trf.12918","journal-title":"Transfusion"},{"issue":"6","key":"3028_CR14","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/j.1537-2995.2012.03904.x","volume":"53","author":"KA Dorsey","year":"2013","unstructured":"Dorsey KA, Moritz ED, Steele WR, Eder AF, Stramer SL (2013) A comparison of human immunodeficiency virus, hepatitis C virus, hepatitis B virus, and human T-lymphotropic virus marker rates for directed versus volunteer blood donations to the American Red Cross during 2005 to 2010. Transfusion 53(6):1250\u20131256. doi: 10.1111\/j.1537-2995.2012.03904.x","journal-title":"Transfusion"},{"key":"3028_CR15","unstructured":"Bloodworks_Northwest (2016) Blood component therapy. http:\/\/www.bloodworksnw.org\/therapy\/"},{"key":"3028_CR16","first-page":"148","volume":"3","author":"J Hardwick","year":"2008","unstructured":"Hardwick J (2008) Blood processing. International Society of Blood Transfusion (ISBT) Science Series 3:148\u2013176","journal-title":"International Society of Blood Transfusion (ISBT) Science Series"},{"key":"3028_CR17","unstructured":"Patient.co.uk (2015) Blood Products for Transfusion"},{"key":"3028_CR18","unstructured":"WHO (2016) Processing of donated blood. http:\/\/www.who.int\/bloodsafety\/processing\/en\/"},{"key":"3028_CR19","unstructured":"WHO (2004) WHO Technical Report, Series No. 924. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. http:\/\/www.who.int\/bloodproducts\/publications\/WHO_TRS_924_A4.pdf"},{"issue":"4","key":"3028_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000381996","volume":"42","author":"MB Funk","year":"2015","unstructured":"Funk MB, Heiden M, Volkers P, Lohmann A, Keller-Stanislawski B (2015) Evaluation of risk minimisation measures for blood components - based on reporting rates of transfusion-transmitted reactions (1997-2013). Transfus med Hemother 42(4):240\u2013246. doi: 10.1159\/000381996","journal-title":"Transfus med Hemother"},{"issue":"8","key":"3028_CR21","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1111\/j.1537-2995.2008.01718.x","volume":"48","author":"MK Hourfar","year":"2008","unstructured":"Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ, German Red Cross NATSG (2008) Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 48(8):1558\u20131566. doi: 10.1111\/j.1537-2995.2008.01718.x","journal-title":"Transfusion"},{"issue":"10","key":"3028_CR22","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1111\/j.1537-2995.2008.01813.x","volume":"48","author":"C Velati","year":"2008","unstructured":"Velati C, Romano L, Fomiatti L, Baruffi L, Zanetti AR, Group SR (2008) Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Transfusion 48(10):2205\u20132213. doi: 10.1111\/j.1537-2995.2008.01813.x","journal-title":"Transfusion"},{"issue":"7","key":"3028_CR23","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1111\/trf.13681","volume":"56","author":"ML Barjas-Castro","year":"2016","unstructured":"Barjas-Castro ML, Angerami RN, Cunha MS, Suzuki A, Nogueira JS, Rocco IM, Maeda AY, Vasami FG, Katz G, Boin IF, Stucchi RS, Resende MR, Esposito DL, de Souza RP, da Fonseca BA, Addas-Carvalho M (2016) Probable transfusion-transmitted Zika virus in Brazil. Transfusion 56(7):1684\u20131688. doi: 10.1111\/trf.13681","journal-title":"Transfusion"},{"key":"3028_CR24","unstructured":"JPAC (2014) Transfusion handbook (5th edition). http:\/\/www.transfusionguidelines.org.uk\/transfusion-handbook"},{"issue":"5","key":"3028_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/01.moh.0000239703.40297.a5","volume":"13","author":"RR Vassallo","year":"2006","unstructured":"Vassallo RR, Murphy S (2006) A critical comparison of platelet preparation methods. Curr Opin Hematol 13(5):323\u2013330. doi: 10.1097\/01.moh.0000239703.40297.a5","journal-title":"Curr Opin Hematol"},{"key":"3028_CR26","unstructured":"Food and Drug Administration (FDA) (2002) Guidance for Industry. Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Blood\/ucm079711.pdf"},{"key":"3028_CR27","unstructured":"Australian Red Cross Blood Service (2017) Donating after travelling. http:\/\/www.donateblood.com.au\/eligibility\/donating-after-travelling"},{"key":"3028_CR28","unstructured":"Transfusion.com.au . (2014) http:\/\/www.transfusion.com.au\/blood_products\/storage"},{"key":"3028_CR29","unstructured":"EDQM (2014) Vision, mission & values. http:\/\/www.edqm.eu\/en\/EDQM-mission-values-604.html"},{"key":"3028_CR30","unstructured":"EDQM (2010) European Committee (Partial Agreement) on Blood Transfusion (CD-P-TS). Symposium on implementation of pathogen reduction technologies for blood components\u2014executive summary"},{"key":"3028_CR31","unstructured":"EDQM (2013) Guide for the preparation, use and quality assurance of blood components: recommendation no. R (95)15. Council of Europe. https:\/\/www.edqm.eu\/en\/news\/guide-preparation-use-and-quality-assurance-blood-components-18th-edition"},{"key":"3028_CR32","unstructured":"EDQM (2010) European Committee (Partial Agreement) on Blood Transfusion (CD-P-TS). The collection, testing and use of blood and blood components in Europe. https:\/\/www.edqm.eu\/sites\/default\/files\/the_collection_testing_and_use_of_blood_and_blood_components_in_europe_2012_report.pdf"},{"key":"3028_CR33","unstructured":"EDQM (2012) Blood and blood components: safety, quality, training and ethical matters concerning preparation, use and quality assurance. https:\/\/www.edqm.eu\/medias\/fichiers\/blood_and_blood_components_recommendations.pdf"},{"key":"3028_CR34","first-page":"78","volume":"5","author":"DV Devine","year":"2010","unstructured":"Devine DV, Howe D (2010) Processing of whole blood into cellular components and plasma. International Society of Blood Transfusion (ISBT) Science Series 5:78\u201382","journal-title":"International Society of Blood Transfusion (ISBT) Science Series"},{"key":"3028_CR35","unstructured":"Food and Drug Administration (FDA) (2011) Guidance for industry\u2014donors of blood and blood components: notification of donor deferral\u2014small entity compliance guide. Accessed at: https:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Blood\/ucm257559.htm"},{"key":"3028_CR36","doi-asserted-by":"publisher","unstructured":"Kaufman RM (2006) Platelets: testing, dosing and the storage lesion\u2014recent advances. Hematology Am Soc Hematol Educ Program 492\u2013496. doi: 10.1182\/asheducation-2006.1.492","DOI":"10.1182\/asheducation-2006.1.492"},{"key":"3028_CR37","doi-asserted-by":"publisher","unstructured":"Muller B, Walther-Wenke G, Kalus M, Alt T, Bux J, Zeiler T, Schottstedt V (2014) Routine bacterial screening of platelet concentrates by flow cytometry and its impact on product safety and supply. Vox Sang. doi: 10.1111\/vox.12214","DOI":"10.1111\/vox.12214"},{"issue":"3","key":"3028_CR38","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1537-2995.2012.03786.x","volume":"53","author":"A Tholpady","year":"2013","unstructured":"Tholpady A, Monson J, Radovancevic R, Klein K, Bracey A (2013) Analysis of prolonged storage on coagulation factor (F)V, FVII, and FVIII in thawed plasma: is it time to extend the expiration date beyond 5 days? Transfusion 53(3):645\u2013650. doi: 10.1111\/j.1537-2995.2012.03786.x","journal-title":"Transfusion"},{"issue":"10","key":"3028_CR39","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1111\/trf.13154","volume":"55","author":"YT Kou","year":"2015","unstructured":"Kou YT, Pagotto F, Hannach B, Ramirez-Arcos S (2015) Fatal false-negative transfusion infection involving a buffy coat platelet pool contaminated with biofilm-positive Staphylococcus epidermidis: a case report. Transfusion 55(10):2384\u20132389. doi: 10.1111\/trf.13154","journal-title":"Transfusion"},{"issue":"5","key":"3028_CR40","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/infdis\/jit254","volume":"208","author":"P Chhabra","year":"2013","unstructured":"Chhabra P, Payne DC, Szilagyi PG, Edwards KM, Staat MA, Shirley SH, Wikswo M, Nix WA, Lu X, Parashar UD, Vinje J (2013) Etiology of viral gastroenteritis in children <5 years of age in the United States, 2008-2009. J Infect dis 208(5):790\u2013800. doi: 10.1093\/infdis\/jit254","journal-title":"J Infect dis"},{"issue":"1","key":"3028_CR41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.tracli.2015.12.004","volume":"23","author":"B Pozzetto","year":"2016","unstructured":"Pozzetto B, Garraud O (2016) New viral risks in blood transfusion by 2016. Transfus Clin Biol 23(1):20\u201327. doi: 10.1016\/j.tracli.2015.12.004","journal-title":"Transfus Clin Biol"},{"key":"3028_CR42","doi-asserted-by":"publisher","unstructured":"Zhang W, Li L, Deng X, Blumel J, Nubling CM, Hunfeld A, Baylis SA, Delwart E (2016) Viral nucleic acids in human plasma pools. Transfusion. doi: 10.1111\/trf.13692","DOI":"10.1111\/trf.13692"},{"key":"3028_CR43","unstructured":"Bundes\u00e4rztekammer (2010) Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (H\u00e4motherapie) http:\/\/www.bundesaerztekammer.de\/aerzte\/medizin-ethik\/haemotherapie-transfusionsmedizin\/haemotherapie\/"},{"key":"3028_CR44","unstructured":"EMA (2011) Guideline on plasma-derived medicinal products. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/07\/WC500109627.pdf"},{"key":"3028_CR45","unstructured":"Baxter_Healthcare (2014) Advate\u00ae; Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000520\/WC500022467.pdf"},{"key":"3028_CR46","unstructured":"Novo_Nordisk (2014) NovoSeven\u00ae; Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000074\/WC500030873.pdf"},{"key":"3028_CR47","unstructured":"Pfizer (2014) BeneFIX\u00ae; Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000139\/WC500020390.pdf"},{"key":"3028_CR48","unstructured":"CSL_Behring (2015) Haemate\u00ae P Product Information http:\/\/www.cslbehring.co.uk\/s1\/cs\/beuk\/1241397147289\/content\/1241397147253\/content.htm"},{"key":"3028_CR49","unstructured":"Novo_Nordisk (2014) Tretten\u00ae; Prescribing Information. http:\/\/www.tretten-us.com\/index.html"},{"issue":"7","key":"3028_CR50","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1056\/NEJM199302183280701","volume":"328","author":"JM Lusher","year":"1993","unstructured":"Lusher JM, Arkin S, Abildgaard CF, Schwartz RS (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate previously untreated patient study group. N Engl J med 328(7):453\u2013459. doi: 10.1056\/NEJM199302183280701","journal-title":"N Engl J med"},{"key":"3028_CR51","unstructured":"Food and Drug Administration (FDA) (2015) News Release: FDA approves first recombinant von Willebrand factor to treat bleeding episodes. Accessed at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm476065.htm"},{"issue":"2","key":"3028_CR52","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1600-0609.2012.01804.x","volume":"89","author":"E Casademunt","year":"2012","unstructured":"Casademunt E, Martinelle K, Jernberg M, Winge S, Tiemeyer M, Biesert L, Knaub S, Walter O, Schroder C (2012) The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics. Eur J Haematol 89(2):165\u2013176. doi: 10.1111\/j.1600-0609.2012.01804.x","journal-title":"Eur J Haematol"},{"issue":"2","key":"3028_CR53","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/biot.200800241","volume":"4","author":"L Grillberger","year":"2009","unstructured":"Grillberger L, Kreil TR, Nasr S, Reiter M (2009) Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J 4(2):186\u2013201. doi: 10.1002\/biot.200800241","journal-title":"Biotechnol J"},{"issue":"Suppl 2","key":"3028_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1351-8216.2001.00115.x","volume":"8","author":"R Jiang","year":"2002","unstructured":"Jiang R, Monroe T, McRogers R, Larson PJ (2002) Manufacturing challenges in the commercial production of recombinant coagulation factor VIII. Haemophilia 8(Suppl 2):1\u20135","journal-title":"Haemophilia"},{"issue":"Suppl 4","key":"3028_CR55","doi-asserted-by":"publisher","first-page":"s64","DOI":"10.2450\/2013.011s","volume":"11","author":"G Calizzani","year":"2013","unstructured":"Calizzani G, Profili S, Candura F, Lanzoni M, Vaglio S, Cannata L, Liumbruno GM, Franchini M, Mannucci PM, Grazzini G (2013) The demand for factor VIII and for factor IX and the toll fractionation product surplus management. Blood Transfus 11(Suppl 4):s64\u2013s76. doi: 10.2450\/2013.011s","journal-title":"Blood Transfus"},{"issue":"10","key":"3028_CR56","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.3324\/haematol.2013.084145","volume":"98","author":"G Di Minno","year":"2013","unstructured":"Di Minno G, Canaro M, Ironside JW, Navarro D, Perno CF, Tiede A, Gurtler L (2013) Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. Haematologica 98(10):1495\u20131498. doi: 10.3324\/haematol.2013.084145","journal-title":"Haematologica"},{"issue":"2","key":"3028_CR57","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/trf.13343","volume":"56","author":"MR Farcet","year":"2016","unstructured":"Farcet MR, Lackner C, Antoine G, Rabel PO, Wieser A, Flicker A, Unger U, Modrof J, Kreil TR (2016) Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes. Transfusion 56(2):383\u2013391. doi: 10.1111\/trf.13343","journal-title":"Transfusion"},{"key":"3028_CR58","doi-asserted-by":"publisher","unstructured":"Di Minno G, Perno CF, Tiede A, Navarro D, Canaro M, Guertler L, Ironside JW (2015) Current concepts in the prevention of pathogen transmission via blood\/plasma-derived products for bleeding disorders. Blood rev. doi: 10.1016\/j.blre.2015.07.004","DOI":"10.1016\/j.blre.2015.07.004"},{"issue":"10029","key":"3028_CR59","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/S0140-6736(16)00581-X","volume":"387","author":"JP Allain","year":"2016","unstructured":"Allain JP, Owusu-Ofori AK, Assennato SM, Marschner S, Goodrich RP, Owusu-Ofori S (2016) Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet 387(10029):1753\u20131761. doi: 10.1016\/S0140-6736(16)00581-X","journal-title":"Lancet"},{"issue":"12","key":"3028_CR60","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1099\/0022-1317-50-12-1030","volume":"50","author":"M Shepel","year":"2001","unstructured":"Shepel M, Boyd J, Luider J, Gibb AP (2001) Interaction of Yersinia enterocolitica and Y. pseudotuberculosis with platelets. J med Microbiol 50(12):1030\u20131038","journal-title":"J med Microbiol"},{"issue":"4","key":"3028_CR61","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2450\/2014.0322-13","volume":"12","author":"G Tolomelli","year":"2014","unstructured":"Tolomelli G, Tazzari PL, Paolucci M, Arpinati M, Landini MP, Pagliaro P (2014) Transfusion-related Listeria monocytogenes infection in a patient with acute myeloid leukaemia. Blood Transfus 12(4):611\u2013614. doi: 10.2450\/2014.0322-13","journal-title":"Blood Transfus"},{"issue":"1","key":"3028_CR62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000324458","volume":"38","author":"R Henschler","year":"2011","unstructured":"Henschler R, Seifried E, Mufti N (2011) Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus med Hemother 38(1):33\u201342. doi: 10.1159\/000324458","journal-title":"Transfus med Hemother"},{"issue":"4","key":"3028_CR63","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1423-0410.1991.tb00907.x","volume":"60","author":"B Lambrecht","year":"1991","unstructured":"Lambrecht B, Mohr H, Knuver-Hopf J, Schmitt H (1991) Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 60(4):207\u2013213","journal-title":"Vox Sang"},{"issue":"5","key":"3028_CR64","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/trf.12423","volume":"54","author":"R Klamroth","year":"2014","unstructured":"Klamroth R, Groner A, Simon TL (2014) Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates. Transfusion 54(5):1406\u20131417. doi: 10.1111\/trf.12423","journal-title":"Transfusion"},{"issue":"1","key":"3028_CR65","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000324160","volume":"38","author":"S Marschner","year":"2011","unstructured":"Marschner S, Goodrich R (2011) Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus med Hemother 38(1):8\u201318. doi: 10.1159\/000324160","journal-title":"Transfus med Hemother"},{"issue":"1","key":"3028_CR66","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000358017","volume":"41","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Geilenkeuser WJ, Sireis W, Seifried E, Hourfar K (2014) Emerging pathogens - how safe is blood? Transfus med Hemother 41(1):10\u201317. doi: 10.1159\/000358017","journal-title":"Transfus med Hemother"},{"issue":"12","key":"3028_CR67","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1111\/j.1537-2995.2009.02347.x","volume":"49","author":"DR Ambruso","year":"2009","unstructured":"Ambruso DR, Thurman G, Marschner S, Goodrich RP (2009) Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates. Transfusion 49(12):2631\u20132636. doi: 10.1111\/j.1537-2995.2009.02347.x","journal-title":"Transfusion"},{"issue":"10","key":"3028_CR68","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1046\/j.1537-2995.2003.00544.x","volume":"43","author":"V Ciaravino","year":"2003","unstructured":"Ciaravino V, McCullough T, Cimino G (2003) The role of toxicology assessment in transfusion medicine. Transfusion 43(10):1481\u20131492","journal-title":"Transfusion"},{"issue":"3","key":"3028_CR69","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1423-0410.2012.01662.x","volume":"104","author":"CV Prowse","year":"2013","unstructured":"Prowse CV (2013) Component pathogen inactivation: a critical review. Vox Sang 104(3):183\u2013199. doi: 10.1111\/j.1423-0410.2012.01662.x","journal-title":"Vox Sang"},{"issue":"2","key":"3028_CR70","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.tmrv.2007.12.003","volume":"22","author":"HL Reddy","year":"2008","unstructured":"Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP (2008) Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus med rev 22(2):133\u2013153. doi: 10.1016\/j.tmrv.2007.12.003","journal-title":"Transfus med rev"},{"issue":"4","key":"3028_CR71","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/bjh.12403","volume":"162","author":"A Seltsam","year":"2013","unstructured":"Seltsam A, Muller TH (2013) Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 162(4):442\u2013454. doi: 10.1111\/bjh.12403","journal-title":"Br J Haematol"},{"issue":"9","key":"3028_CR72","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1111\/j.1537-2995.2005.00551.x","volume":"45","author":"H Yarranton","year":"2005","unstructured":"Yarranton H, Lawrie AS, Mackie IJ, Pinkoski L, Corash L, Machin SJ (2005) Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light. Transfusion 45(9):1453\u20131458. doi: 10.1111\/j.1537-2995.2005.00551.x","journal-title":"Transfusion"},{"issue":"1\u20132","key":"3028_CR73","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.mrgentox.2007.02.008","volume":"630","author":"RR Tice","year":"2007","unstructured":"Tice RR, Gatehouse D, Kirkland D, Speit G (2007) The pathogen reduction treatment of platelets with S-59 HCl (Amotosalen) plus ultraviolet a light: genotoxicity profile and hazard assessment. Mutat res 630(1\u20132):50\u201368. doi: 10.1016\/j.mrgentox.2007.02.008","journal-title":"Mutat res"},{"issue":"4","key":"3028_CR74","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/vox.12287","volume":"109","author":"F Knutson","year":"2015","unstructured":"Knutson F, Osselaer J, Pierelli L, Lozano M, Cid J, Tardivel R, Garraud O, Hervig T, Domanovic D, Cukjati M, Gudmundson S, Hjalmarsdottir IB, Castrillo A, Gonzalez R, Brihante D, Santos M, Schlenke P, Elliott A, Lin JS, Tappe D, Stassinopoulos A, Green J, Corash L (2015) A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 109(4):343\u2013352. doi: 10.1111\/vox.12287","journal-title":"Vox Sang"},{"issue":"6","key":"3028_CR75","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/MOH.0b013e328365a18f","volume":"20","author":"M Lozano","year":"2013","unstructured":"Lozano M, Cid J (2013) Pathogen inactivation: coming of age. Curr Opin Hematol 20(6):540\u2013545. doi: 10.1097\/MOH.0b013e328365a18f","journal-title":"Curr Opin Hematol"},{"key":"3028_CR76","unstructured":"Corten L SL, Liu W, et al (2011) Third International Meeting on Emerging Diseases and Surveillance: Vienna, Austria. Pathogen inactivation of blood components for prevention of transfusion-transmitted emerging infectious diseases: the INTERCEPT Blood System. http:\/\/www.interceptbloodsystem.com\/resource-center\/scientific-publications\/intercept-conference-abstracts\/2011"},{"issue":"11","key":"3028_CR77","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1111\/trf.12713","volume":"54","author":"D Musso","year":"2014","unstructured":"Musso D, Richard V, Broult J, Cao-Lormeau VM (2014) Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination. Transfusion 54(11):2924\u20132930. doi: 10.1111\/trf.12713","journal-title":"Transfusion"},{"issue":"2","key":"3028_CR78","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.transci.2015.02.013","volume":"52","author":"J Irsch","year":"2015","unstructured":"Irsch J, Seghatchian J (2015) Update on pathogen inactivation treatment of plasma, with the INTERCEPT blood system: current position on methodological, clinical and regulatory aspects. Transfus Apher Sci 52(2):240\u2013244. doi: 10.1016\/j.transci.2015.02.013","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"3028_CR79","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/trf.13271","volume":"56","author":"M Aubry","year":"2016","unstructured":"Aubry M, Richard V, Green J, Broult J, Musso D (2016) Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination. Transfusion 56(1):33\u201340. doi: 10.1111\/trf.13271","journal-title":"Transfusion"},{"issue":"2","key":"3028_CR80","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2141.2010.08227.x","volume":"150","author":"JL Kerkhoffs","year":"2010","unstructured":"Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ, Dutch-Belgian Hcg (2010) Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 150(2):209\u2013217. doi: 10.1111\/j.1365-2141.2010.08227.x","journal-title":"Br J Haematol"},{"issue":"12","key":"3028_CR81","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1111\/j.1537-2995.2005.00639.x","volume":"45","author":"E Snyder","year":"2005","unstructured":"Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L, Conlan MG, Group SS (2005) Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 45(12):1864\u20131875. doi: 10.1111\/j.1537-2995.2005.00639.x","journal-title":"Transfusion"},{"issue":"3","key":"3028_CR82","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000445195","volume":"43","author":"P Gowland","year":"2016","unstructured":"Gowland P, Fontana S, Stolz M, Andina N, Niederhauser C (2016) Parvovirus B19 passive transmission by transfusion of intercept(R) blood system-treated platelet concentrate. Transfus med Hemother 43(3):198\u2013202. doi: 10.1159\/000445195","journal-title":"Transfus med Hemother"},{"issue":"Suppl 1","key":"3028_CR83","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1111\/trf.13530","volume":"56","author":"L Corash","year":"2016","unstructured":"Corash L, Benjamin RJ (2016) The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen-ultraviolet A pathogen reduction treatment model. Transfusion 56(Suppl 1):S29\u2013S38. doi: 10.1111\/trf.13530","journal-title":"Transfusion"},{"issue":"8","key":"3028_CR84","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/prca.201500124","volume":"10","author":"A Osman","year":"2016","unstructured":"Osman A, Hitzler WE, Provost P (2016) Peculiarities of studying the effects of pathogen reduction technologies on platelets. Proteomics Clin Appl 10(8):805\u2013815. doi: 10.1002\/prca.201500124","journal-title":"Proteomics Clin Appl"},{"key":"3028_CR85","doi-asserted-by":"publisher","unstructured":"Laughhunn A, Santa Maria F, Broult J, Lanteri MC, Stassinopoulos A, Musso D, Aubry M (2017) Amustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell components. Transfusion. doi: 10.1111\/trf.13993","DOI":"10.1111\/trf.13993"},{"issue":"7","key":"3028_CR86","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1111\/trf.12545","volume":"54","author":"KM Winter","year":"2014","unstructured":"Winter KM, Johnson L, Kwok M, Vidovic D, Hyland RA, Mufti N, Erickson A, Marks DC (2014) Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment. Transfusion 54(7):1798\u20131807. doi: 10.1111\/trf.12545","journal-title":"Transfusion"},{"key":"3028_CR87","doi-asserted-by":"publisher","unstructured":"Cancelas JA, Gottschall JL, Rugg N, Graminske S, Schott MA, North A, Huang N, Mufti N, Erickson A, Rico S, Corash L (2017) Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study. Vox Sang. doi: 10.1111\/vox.12500","DOI":"10.1111\/vox.12500"},{"issue":"9","key":"3028_CR88","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/trf.13123","volume":"55","author":"M Abonnenc","year":"2015","unstructured":"Abonnenc M, Sonego G, Crettaz D, Aliotta A, Prudent M, Tissot JD, Lion N (2015) In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin\/UVB-treated platelet concentrates. Transfusion 55(9):2219\u20132230. doi: 10.1111\/trf.13123","journal-title":"Transfusion"},{"issue":"6 Pt 2","key":"3028_CR89","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1111\/trf.13519","volume":"56","author":"HM Faddy","year":"2016","unstructured":"Faddy HM, Fryk JJ, Prow NA, Watterson D, Young PR, Hall RA, Tolksdorf F, Sumian C, Gravemann U, Seltsam A, Marks DC (2016) Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light. Transfusion 56(6 Pt 2):1548\u20131555. doi: 10.1111\/trf.13519","journal-title":"Transfusion"},{"issue":"Suppl 1","key":"3028_CR90","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1111\/trf.13393","volume":"56","author":"AP Cap","year":"2016","unstructured":"Cap AP, Pidcoke HF, Keil SD, Staples HM, Anantpadma M, Carrion R Jr, Davey RA, Frazer-Abel A, Taylor AL, Gonzales R, Patterson JL, Goodrich RP (2016) Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro. Transfusion 56(Suppl 1):S6\u201315. doi: 10.1111\/trf.13393","journal-title":"Transfusion"},{"key":"3028_CR91","unstructured":"Ellery B, Mundy L, Juneia V, Braunack-Mayer, Merlin T (2011). Queensland Health-PACT on Technology, Australia and New Zealand. Available from: https:\/\/www.health.qld.gov.au\/__data\/assets\/pdf_file\/0026\/427247\/wp030.pdf"},{"issue":"2","key":"3028_CR92","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.transci.2013.07.023","volume":"49","author":"J Seghatchian","year":"2013","unstructured":"Seghatchian J, Putter JS (2013) Pathogen inactivation of whole blood and red cell components: an overview of concept, design, developments, criteria of acceptability and storage lesion. Transfus Apher Sci 49(2):357\u2013363. doi: 10.1016\/j.transci.2013.07.023","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"3028_CR93","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1423-0410.1992.tb05097.x","volume":"63","author":"P Hellstern","year":"1992","unstructured":"Hellstern P, Sachse H, Schwinn H, Oberfrank K (1992) Manufacture and in vitro characterization of a solvent\/detergent-treated human plasma. Vox Sang 63(3):178\u2013185","journal-title":"Vox Sang"},{"issue":"1","key":"3028_CR94","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000323552","volume":"38","author":"P Hellstern","year":"2011","unstructured":"Hellstern P, Solheim BG (2011) The use of solvent\/detergent treatment in pathogen reduction of plasma. Transfus med Hemother 38(1):65\u201370. doi: 10.1159\/000323552","journal-title":"Transfus med Hemother"},{"issue":"3","key":"3028_CR95","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood.V79.3.826.826","volume":"79","author":"B Horowitz","year":"1992","unstructured":"Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW (1992) Solvent\/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 79(3):826\u2013831","journal-title":"Blood"},{"issue":"8483","key":"3028_CR96","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0140-6736(86)91101-3","volume":"1","author":"AM Prince","year":"1986","unstructured":"Prince AM, Horowitz B, Brotman B (1986) Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Lancet 1(8483):706\u2013710","journal-title":"Lancet"},{"issue":"1","key":"3028_CR97","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/187152611794407746","volume":"11","author":"PF Lindholm","year":"2011","unstructured":"Lindholm PF, Annen K, Ramsey G (2011) Approaches to minimize infection risk in blood banking and transfusion practice. Infect Disord Drug Targets 11(1):45\u201356","journal-title":"Infect Disord Drug Targets"},{"issue":"1","key":"3028_CR98","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/MOH.0000000000000101","volume":"22","author":"JY Douet","year":"2015","unstructured":"Douet JY, Bujdoso R, Andreoletti O (2015) Leukoreduction and blood-borne vCJD transmission risk. Curr Opin Hematol 22(1):36\u201340. doi: 10.1097\/MOH.0000000000000101","journal-title":"Curr Opin Hematol"},{"key":"3028_CR99","doi-asserted-by":"publisher","unstructured":"Lescoutra-Etchegaray N, Jaffre N, Sumian C, Durand V, Correia E, Mikol J, Luccantoni-Freire S, Culeux A, Deslys JP, Comoy EE (2015) Evaluation of the protection of primates transfused with variant Creutzfeldt-Jakob disease-infected blood products filtered with prion removal devices: a 5-year update. Transfusion. doi: 10.1111\/trf.12999","DOI":"10.1111\/trf.12999"},{"issue":"2","key":"3028_CR100","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.transci.2015.02.012","volume":"52","author":"A Neisser-Svae","year":"2015","unstructured":"Neisser-Svae A, Seghatchian J (2015) The state of the art of removal of prion proteins in SD-FFP, by specific prion affinity chromatography and its impact on the hemostatic characteristics of the product. Transfus Apher Sci 52(2):237\u2013239. doi: 10.1016\/j.transci.2015.02.012","journal-title":"Transfus Apher Sci"},{"key":"3028_CR101","unstructured":"The National Cjd Research & Surveillance Unit (NCJDRSU). Creutzfeldt-Jakob Disease Surveillance in the UK. 24th Annual Report (2015). Available at: http:\/\/www.cjd.ed.ac.uk\/ . Accessed March 2017"},{"issue":"370","key":"3028_CR102","doi-asserted-by":"publisher","first-page":"370ra182","DOI":"10.1126\/scitranslmed.aag1257","volume":"8","author":"D Bougard","year":"2016","unstructured":"Bougard D, Brandel JP, Belondrade M, Beringue V, Segarra C, Fleury H, Laplanche JL, Mayran C, Nicot S, Green A, Welaratne A, Narbey D, Fournier-Wirth C, Knight R, Will R, Tiberghien P, Haik S, Coste J (2016) Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Sci Transl med 8(370):370ra182. doi: 10.1126\/scitranslmed.aag1257","journal-title":"Sci Transl med"},{"issue":"370","key":"3028_CR103","doi-asserted-by":"publisher","first-page":"370ra183","DOI":"10.1126\/scitranslmed.aaf6188","volume":"8","author":"L Concha-Marambio","year":"2016","unstructured":"Concha-Marambio L, Pritzkow S, Moda F, Tagliavini F, Ironside JW, Schulz PE, Soto C (2016) Detection of prions in blood from patients with variant Creutzfeldt-Jakob disease. Sci Transl med 8(370):370ra183. doi: 10.1126\/scitranslmed.aaf6188","journal-title":"Sci Transl med"},{"issue":"Suppl 1","key":"3028_CR104","doi-asserted-by":"publisher","first-page":"65S","DOI":"10.1111\/j.1537-2995.2012.03663.x","volume":"52","author":"S Pandey","year":"2012","unstructured":"Pandey S, Vyas GN (2012) Adverse effects of plasma transfusion. Transfusion 52(Suppl 1):65S\u201379S. doi: 10.1111\/j.1537-2995.2012.03663.x","journal-title":"Transfusion"},{"issue":"21","key":"3028_CR105","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Hanagavadi S, Varadarajan R, Karimi M, Manglani MV, Ross C, Young G, Seth T, Apte S, Nayak DM, Santagostino E, Mancuso ME, Sandoval Gonzalez AC, Mahlangu JN, Bonanad Boix S, Cerqueira M, Ewing NP, Male C, Owaidah T, Soto Arellano V, Kobrinsky NL, Majumdar S, Perez Garrido R, Sachdeva A, Simpson M, Thomas M, Zanon E, Antmen B, Kavakli K, Manco-Johnson MJ, Martinez M, Marzouka E, Mazzucconi MG, Neme D, Palomo Bravo A, Paredes Aguilera R, Prezotti A, Schmitt K, Wicklund BM, Zulfikar B, Rosendaal FR (2016) A randomized trial of factor VIII and neutralizing antibodies in hemophilia a. N Engl J med 374(21):2054\u20132064. doi: 10.1056\/NEJMoa1516437","journal-title":"N Engl J med"},{"key":"3028_CR106","unstructured":"Hashemi SM, Other J, Another C (2015) Risk for inhibitor development in severe hemophilia A is not associated with FVIII product class or with high von-Willebrand content\u2014oral presentation at ISTH 2015"},{"issue":"3","key":"3028_CR107","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1056\/NEJMoa1208024","volume":"368","author":"SC Gouw","year":"2013","unstructured":"Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, Makipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM, PedNet, Group RS (2013) Factor VIII products and inhibitor development in severe hemophilia A. N Engl J med 368(3):231\u2013239. doi: 10.1056\/NEJMoa1208024","journal-title":"N Engl J med"},{"issue":"4","key":"3028_CR108","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1423-0410.1992.tb01230.x","volume":"63","author":"Y Piquet","year":"1992","unstructured":"Piquet Y, Janvier G, Selosse P, Doutremepuich C, Jouneau J, Nicolle G, Platel D, Vezon G (1992) Virus inactivation of fresh frozen plasma by a solvent detergent procedure: biological results. Vox Sang 63(4):251\u2013256","journal-title":"Vox Sang"},{"issue":"12","key":"3028_CR109","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1046\/j.1537-2995.2001.41121548.x","volume":"41","author":"R Atance","year":"2001","unstructured":"Atance R, Pereira A, Ramirez B (2001) Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 41(12):1548\u20131552","journal-title":"Transfusion"},{"issue":"6","key":"3028_CR110","first-page":"155","volume":"19","author":"D Barz","year":"1994","unstructured":"Barz D (1994) Detection of antigen structures in blood cells in various prepared plasma transfusions. Anaesthesiol Reanim 19(6):155\u2013158","journal-title":"Anaesthesiol Reanim"},{"issue":"5","key":"3028_CR111","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/bja\/aer009","volume":"106","author":"P Dewachter","year":"2011","unstructured":"Dewachter P, Castro S, Nicaise-Roland P, Chollet-Martin S, Le Beller C, Lillo-le-Louet A, Mouton-Faivre C (2011) Anaphylactic reaction after methylene blue-treated plasma transfusion. Br J Anaesth 106(5):687\u2013689. doi: 10.1093\/bja\/aer009","journal-title":"Br J Anaesth"},{"issue":"1","key":"3028_CR112","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1537-2995.2010.02800.x","volume":"51","author":"K Nubret","year":"2011","unstructured":"Nubret K, Delhoume M, Orsel I, Laudy JS, Sellami M, Nathan N (2011) Anaphylactic shock to fresh-frozen plasma inactivated with methylene blue. Transfusion 51(1):125\u2013128. doi: 10.1111\/j.1537-2995.2010.02800.x","journal-title":"Transfusion"},{"issue":"5","key":"3028_CR113","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1046\/j.1365-2141.2003.04360.x","volume":"121","author":"H Yarranton","year":"2003","unstructured":"Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ (2003) Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 121(5):778\u2013785","journal-title":"Br J Haematol"},{"issue":"2","key":"3028_CR114","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1111\/hae.12334","volume":"20","author":"M Franchini","year":"2014","unstructured":"Franchini M, Coppola A, Rocino A, Zanon E, Morfini M, Italian Association of Haemophilia Centers AWG, Accorsi A, Aru AB, Biasoli C, Cantori I, Castaman G, Cesaro S, Ciabatta C, De Cristofaro R, Delios G, Di Minno G, D\u2019Inca M, Dragani A, Ettorre CP, Gagliano F, Gamba G, Gandini G, Giordano P, Giuffrida G, Gresele P, Latella C, Luciani M, Margaglione M, Marietta M, Mazzucconi MG, Messina M, Molinari AC, Notarangelo LD, Oliovecchio E, Peyvandi F, Piseddu G, Rossetti G, Rossi V, Santagostino E, Schiavoni M, Schinco P, Serino ML, Tagliaferri A, Testa S (2014) Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey. Haemophilia 20(2):e128\u2013e135. doi: 10.1111\/hae.12334","journal-title":"Haemophilia"},{"issue":"11","key":"3028_CR115","doi-asserted-by":"publisher","first-page":"e3306","DOI":"10.1371\/journal.pntd.0003306","volume":"8","author":"DS Shepard","year":"2014","unstructured":"Shepard DS, Undurraga EA, Betancourt-Cravioto M, Guzman MG, Halstead SB, Harris E, Mudin RN, Murray KO, Tapia-Conyer R, Gubler DJ (2014) Approaches to refining estimates of global burden and economics of dengue. PLoS Negl Trop Dis 8(11):e3306. doi: 10.1371\/journal.pntd.0003306","journal-title":"PLoS Negl Trop Dis"},{"key":"3028_CR116","doi-asserted-by":"publisher","unstructured":"Shepard DS, Undurraga EA, Halasa YA, Stanaway JD (2016) The global economic burden of dengue: a systematic analysis. Lancet Infect dis. doi: 10.1016\/S1473-3099(16)00146-8","DOI":"10.1016\/S1473-3099(16)00146-8"},{"issue":"4","key":"3028_CR117","first-page":"199","volume":"6","author":"GM Liumbruno","year":"2008","unstructured":"Liumbruno GM, Calteri D, Petropulacos K, Mattivi A, Po C, Macini P, Tomasini I, Zucchelli P, Silvestri AR, Sambri V, Pupella S, Catalano L, Piccinini V, Calizzani G, Grazzini G (2008) The chikungunya epidemic in Italy and its repercussion on the blood system. Blood Transfus 6(4):199\u2013210","journal-title":"Blood Transfus"},{"issue":"13","key":"3028_CR118","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1056\/NEJMoa030969","volume":"349","author":"LN Pealer","year":"2003","unstructured":"Pealer LN, Marfin AA, Petersen LR, Lanciotti RS, Page PL, Stramer SL, Stobierski MG, Signs K, Newman B, Kapoor H, Goodman JL, Chamberland ME, West Nile Virus Transmission Investigation T (2003) Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J med 349(13):1236\u20131245. doi: 10.1056\/NEJMoa030969","journal-title":"N Engl J med"},{"issue":"4","key":"3028_CR119","first-page":"287","volume":"39","author":"D Macciocchi","year":"2016","unstructured":"Macciocchi D, Lanini S, Vairo F, Zumla A, Figueiredo LT, Lauria FN, Strada G, Brouqui P, Puro V, Krishna S, Kremsner P, Scognamiglio P, Kohler C, Nicastri E, Di Caro A, Cieri RM, Ioannidis JP, Kobinger G, Burattini MN, Ippolito G (2016) Short-term economic impact of the Zika virus outbreak. New Microbiol 39(4):287\u2013289","journal-title":"New Microbiol"},{"issue":"3","key":"3028_CR120","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1365-2141.2011.08635.x","volume":"153","author":"M Lozano","year":"2011","unstructured":"Lozano M, Knutson F, Tardivel R, Cid J, Maymo RM, Lof H, Roddie H, Pelly J, Docherty A, Sherman C, Lin L, Propst M, Corash L, Prowse C (2011) A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 153(3):393\u2013401. doi: 10.1111\/j.1365-2141.2011.08635.x","journal-title":"Br J Haematol"},{"issue":"7","key":"3028_CR121","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/j.1537-2995.2012.03928.x","volume":"53","author":"S Kleinman","year":"2013","unstructured":"Kleinman S, Reed W, Stassinopoulos A (2013) A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion 53(7):1603\u20131618. doi: 10.1111\/j.1537-2995.2012.03928.x","journal-title":"Transfusion"},{"key":"3028_CR122","unstructured":"SaBTO: Advisory Committee on the Safety of Blood, Tissues and Organs. Pathogen Inactivation of Platelets: Report of the SaBTO Working Group (2014). Accessed at: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/324354\/SaBTO_platelets_report.pdf"},{"issue":"1","key":"3028_CR123","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/trf.12232","volume":"54","author":"E Girona-Llobera","year":"2014","unstructured":"Girona-Llobera E, Jimenez-Marco T, Galmes-Trueba A, Muncunill J, Serret C, Serra N, Sedeno M (2014) Reducing the financial impact of pathogen inactivation technology for platelet components: our experience. Transfusion 54(1):158\u2013168. doi: 10.1111\/trf.12232","journal-title":"Transfusion"},{"issue":"1","key":"3028_CR124","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1365-3148.2006.00644.x","volume":"16","author":"K Moeremans","year":"2006","unstructured":"Moeremans K, Warie H, Annemans L (2006) Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfus Med 16(1):17\u201330. doi: 10.1111\/j.1365-3148.2006.00644.x","journal-title":"Transfus Med"},{"issue":"5","key":"3028_CR125","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-3148.2005.00609.x","volume":"15","author":"MJ Postma","year":"2005","unstructured":"Postma MJ, van Hulst M, De Wolf JT, Botteman M, Staginnus U (2005) Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med 15(5):379\u2013387. doi: 10.1111\/j.1365-3148.2005.00609.x","journal-title":"Transfus Med"},{"issue":"10","key":"3028_CR126","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/trf.13149","volume":"55","author":"J McCullough","year":"2015","unstructured":"McCullough J, Goldfinger D, Gorlin J, Riley WJ, Sandhu H, Stowell C, Ward D, Clay M, Pulkrabek S, Chrebtow V, Stassinopoulos A (2015) Cost implications of implementation of pathogen-inactivated platelets. Transfusion 55(10):2312\u20132320. doi: 10.1111\/trf.13149","journal-title":"Transfusion"},{"issue":"3","key":"3028_CR127","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/vox.12158","volume":"107","author":"SY Kwon","year":"2014","unstructured":"Kwon SY, Kim IS, Bae JE, Kang JW, Cho YJ, Cho NS, Lee SW (2014) Pathogen inactivation efficacy of Mirasol PRT system and intercept blood system for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma. Vox Sang 107(3):254\u2013260. doi: 10.1111\/vox.12158","journal-title":"Vox Sang"},{"key":"3028_CR128","unstructured":"Food and Drug Administration (FDA) (2007) Guidance for Industry and FDA Review Staff: Collection of Platelets by Automated Methods. Accessed at: https:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Blood\/ucm073382.htm . http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Blood\/ucm073382.htm"},{"key":"3028_CR129","unstructured":"American Association of Blood Banks (AABB) (2015) Blood and Blood Components. Accessed at: http:\/\/www.aabb.org\/advocacy\/regulatorygovernment\/bloodcomponents\/Pages\/default.aspx"},{"key":"3028_CR130","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1146\/annurev-genom-092010-110722","volume":"14","author":"DM Lautenbach","year":"2013","unstructured":"Lautenbach DM, Christensen KD, Sparks JA, Green RC (2013) Communicating genetic risk information for common disorders in the era of genomic medicine. Annu Rev Genomics Hum Genet 14:491\u2013513. doi: 10.1146\/annurev-genom-092010-110722","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"6","key":"3028_CR131","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/hex.12406","volume":"19","author":"AK Smit","year":"2016","unstructured":"Smit AK, Keogh LA, Hersch J, Newson AJ, Butow P, Williams G, Cust AE (2016) Public preferences for communicating personal genomic risk information: a focus group study. Health Expect 19(6):1203\u20131214. doi: 10.1111\/hex.12406","journal-title":"Health Expect"},{"issue":"7113","key":"3028_CR132","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/bmj.315.7113.939","volume":"315","author":"KC Calman","year":"1997","unstructured":"Calman KC, Royston GH (1997) Risk language and dialects. BMJ 315(7113):939\u2013942","journal-title":"BMJ"},{"key":"3028_CR133","doi-asserted-by":"publisher","unstructured":"Meybohm P, Richards T, Isbister J, Hofmann A, Shander A, Goodnough LT, Munoz M, Gombotz H, Weber CF, Choorapoikayil S, Spahn DR, Zacharowski K (2016) Patient blood management bundles to facilitate implementation. Transfus med rev. doi: 10.1016\/j.tmrv.2016.05.012","DOI":"10.1016\/j.tmrv.2016.05.012"},{"issue":"1","key":"3028_CR134","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A, Treatment Guidelines Working Group on Behalf of The World Federation Of H (2013) Guidelines for the management of hemophilia. Haemophilia 19(1):e1\u201347. doi: 10.1111\/j.1365-2516.2012.02909.x","journal-title":"Haemophilia"},{"key":"3028_CR135","unstructured":"Bundes\u00e4rztekammer (2008) Cross-sectional guidelines for therapy with blood components and plasma derivatives, 4th edn (revised). http:\/\/www.bundesaerztekammer.de\/fileadmin\/user_upload\/downloads\/Querschnittsleitlinie_Gesamtdokument-englisch_07032011.pdf"},{"issue":"4","key":"3028_CR136","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2450\/2014.0223-14","volume":"12","author":"A Rocino","year":"2014","unstructured":"Rocino A, Coppola A, Franchini M, Castaman G, Santoro C, Zanon E, Santagostino E, Morfini M, Italian Association of Haemophilia Centres Working P (2014) Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus 12(4):575\u2013598. doi: 10.2450\/2014.0223-14","journal-title":"Blood Transfus"},{"key":"3028_CR137","unstructured":"Associazione Italiana Centri Emofilia (AICE) (2015) Informed consent form for haemophilia treaters of Italy (Consenso Informato e informativa). Accessed at: http:\/\/www.aiceonline.org\/"},{"key":"3028_CR138","unstructured":"Hemoterapia SEdHy (2012) Est\u00e1ndares en Transfusi\u00f3n Sangu\u00ednea \u2013 Fundacion CAT (4th edition) http:\/\/www.catransfusion.es\/media\/upload\/arxius\/documentos\/ANEXO_ESTANDARES_2012.pdf"},{"key":"3028_CR139","unstructured":"Hospital SEU (2015) Informed consent form for transfusion"},{"issue":"4","key":"3028_CR140","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1309\/AJCP2TN5ODJLYGQR","volume":"138","author":"M Friedman","year":"2012","unstructured":"Friedman M, Arja W, Batra R, Daniel S, Hoehn D, Paniz AM, Selegean S, Slova D, Srivastava S, Vergara N (2012) Informed consent for blood transfusion: what do medicine residents tell? What do patients understand? Am J Clin Pathol 138(4):559\u2013565. doi: 10.1309\/AJCP2TN5ODJLYGQR","journal-title":"Am J Clin Pathol"},{"key":"3028_CR141","unstructured":"American Association of Blood Banks (AABB) (2009) Standards for blood banks and transfusion services, 26th ed. Accessed at: http:\/\/www.aabb.org\/"},{"issue":"2","key":"3028_CR142","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1309\/AJCPP85EXSGZORYZ","volume":"144","author":"SR Vossoughi","year":"2015","unstructured":"Vossoughi SR, Macauley R, Sazama K, Fung MK (2015) Attitudes, practices, and training on informed consent for transfusions and procedures: a survey of medical students and physicians. Am J Clin Pathol 144(2):315\u2013321. doi: 10.1309\/AJCPP85EXSGZORYZ","journal-title":"Am J Clin Pathol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3028-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3028-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3028-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T10:09:51Z","timestamp":1602324591000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3028-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,18]]},"references-count":142,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3028"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3028-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,18]]}}}